EGF and neoplasm: Since 2004, conventional chemotherapy is combined with targeted monoclonal antibody therapies specifically directed against vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) and their receptors to block angiogenic and proliferative tumor actions (Mihalache and Rogoveanu, 2014), (Mayer, 2009).